Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in ER-positive/HER2-negative early breast cancer
2013-000568-28Phase 2Completed
- Sponsor
- Genentech
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Estrogen receptor-positive HER2-negative breast cancer (ER+/HER2-) comparing Letrozole plus taselisib with Letrozole plus placebo (2 arms). Primary endpoint: Co-primary efficacy endpoints. Started May 2014; status: completed.
02
Drugs
taselisib / pictilisib
03
Conditions
Estrogen receptor-positive HER2-negative breast cancer (ER+/HER2-)
Beyond the preview
Go deeper on 2013-000568-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000568-28.